Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

This time may be different

Nature Biotechnology volume 34, pages 25–30 (2016)Cite this article

Subjects

The markets may be softening on biotech, but overall the sector remains in an incredibly strong environment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biotech's five-year bull market.
Figure 2: Biotech's current performance in context of long-term investment cycles.
Figure 3: This time is different.
Figure 4: Three things that are not different in biotech today.

References

  1. Ernst & Young. Biotech '92: Promise to Reality. Ernst & Young Annual Biotech Report. 1992 (Ernst & Young, New York, 1992).

  2. Slud, M. Boom time for biotech. CNNMoney (22 February 2000). http://money.cnn.com/2000/02/22/companies/biotech/

    Google Scholar 

  3. Thomas, D. & Wessel, C. Emerging therapeutic company investment and deal trends (Biotechnology Industry Organization, 11 June 2015). https://www.bio.org/sites/default/files/BIO%20Emerging%20Therapeutic%20Company%20Report%20June%2011%202015.pdf

  4. Ernst & Young. Beyond Borders: Reaching New Heights. Ernst & Young Annual Biotech Report 2015 (Ernst & Young, New York, 2015). http://www.ey.com/Publication/vwLUAssets/EY-beyond-borders-2015/$FILE/EY-beyond-borders-2015.pdf

  5. Schulze, U. et al. Nat. Rev. Drug Discov. 13, 331–332 (2014).

    Article  CAS  Google Scholar 

  6. Smietana, K. et al. Nat. Rev. Drug Discov. 14, 455–456 (2015).

    Article  CAS  Google Scholar 

  7. Booth, B. et al. Improving the Pharma Research Pipeline McKinsey Quarterly, Web Exclusive August 2004 (Mckinsey, New York, 2004)

    Google Scholar 

Download references

Acknowledgements

The author would like to thank his colleagues at Atlas Venture for their helpful perspectives and input into the sector, and both K. Margeson and E. Silva for data and graphical support.

Author information

Authors and Affiliations

  1. Bruce L. Booth (@LifeSciVC; http://www.lifescivc.com) is a partner at Atlas Venture, Cambridge, Massachusetts, USA.,

    Bruce L Booth

  2. http://www.lifescivc.com) is a partner at Atlas Venture, Cambridge, Massachusetts, USA.,

    Bruce L Booth

Authors
  1. Bruce L Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce L Booth.

Ethics declarations

Competing interests

B.L.B. participates in partnerships that invest in biotech venture capital and has a pecuniary financial interest in the success of those investments.

Source data

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Booth, B. This time may be different. Nat Biotechnol 34, 25–30 (2016). https://doi.org/10.1038/nbt.3452

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3452

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing